Fig. 1

RT plus YM101 potentiates tumor suppression across multiple murine models. (a-c) 4T1 tumor model. (a) The representative tumors photograph and schematic of treatment schedules. (b) Tumor volume expressed as the mean ± SEM. Data are from three independent experiments with 6–9 mice per group in each experiment. (c) Tumor weights on day 12 (n = 6 per group). (d-f) CT26 tumor model. (d) The representative tumors photograph and schematic of treatment schedules. (e) Tumor volume expressed as the mean ± SEM. Data are from two independent experiments with 6–9 mice per group in each experiment. (f) Tumor weights on day 12 (n = 6 per group). (g-i) MC38 tumor model. (g) The representative tumors photograph and schematic of treatment schedules. (h) Tumor volume expressed as the mean ± SEM. (i) Tumor weights on day 14 (n = 6 per group). (j-k) Survival analysis (via Kaplan-Meier) in 4T1 and CT26 tumor-bearing mice were presented (n = 9 per group). The P values were calculated by one-way ANOVA followed by Dunnett’s multiple comparisons test. *P < 0.05; **P < 0.01; ***P < 0.001 and ****P < 0.0001 denote the significant difference relative to RT plus YM101 group when not marked with lines